Stock Analysis on Net
Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Beginner level

Thermo Fisher Scientific Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel LibreOffice Calc
Apr 3, 2021 Dec 31, 2020 Sep 26, 2020 Jun 27, 2020 Mar 28, 2020 Dec 31, 2019 Sep 28, 2019 Jun 29, 2019 Mar 30, 2019 Dec 31, 2018 Sep 29, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jul 1, 2017 Apr 1, 2017 Dec 31, 2016 Oct 1, 2016 Jul 2, 2016 Apr 2, 2016
Short-term obligations and current maturities of long-term obligations 0.01 3.81 0.00 1.10 1.26 1.16 1.17 4.10 2.40 2.26 1.84 3.09 4.97 3.77 4.93 3.31 4.07 2.73 4.11 5.95 7.88
Accounts payable 3.25 3.15 2.66 2.25 2.72 3.29 2.92 2.40 2.63 2.87 2.44 2.45 2.39 2.52 2.01 2.11 2.23 2.02 1.96 2.00 1.99
Accrued payroll and employee benefits 1.99 2.77 2.40 1.92 1.29 1.73 1.56 1.40 1.27 1.75 1.48 1.36 1.14 1.62 1.38 1.32 1.13 1.54 1.27 1.23 0.98
Contract liabilities 2.12 1.84 1.63 1.58 1.60 1.57 1.66 1.83 1.74 1.44 1.45 1.47 1.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.27 1.33 1.17 1.17 1.06 1.03 0.85 0.84
Other accrued expenses 3.24 3.35 3.03 2.91 2.50 2.87 2.99 3.23 2.57 2.61 2.22 2.42 2.39 3.26 2.91 3.01 2.88 3.24 2.59 3.04 3.04
Current liabilities 10.61% 14.92% 9.72% 9.76% 9.37% 10.61% 10.30% 12.95% 10.61% 10.93% 9.43% 10.79% 12.50% 12.44% 12.56% 10.91% 11.47% 10.60% 10.96% 13.08% 14.72%
Deferred income taxes 2.86 2.60 2.39 2.84 3.64 3.75 3.53 3.34 3.86 4.03 4.63 4.69 4.61 4.88 5.60 4.99 5.33 5.57 5.65 5.87 6.27
Other long-term liabilities 5.08 4.84 5.29 5.39 5.56 5.55 5.53 5.40 5.48 4.47 4.87 4.82 4.70 4.53 3.37 3.16 3.17 3.43 2.99 3.19 3.16
Long-term obligations, excluding current maturities 28.27 27.67 32.92 33.51 32.77 29.25 28.90 28.74 30.24 31.51 32.25 31.96 32.03 33.30 34.35 32.80 32.87 33.49 35.28 27.53 27.13
Long-term liabilities 36.22% 35.11% 40.60% 41.73% 41.97% 38.56% 37.95% 37.49% 39.58% 40.01% 41.74% 41.47% 41.33% 42.72% 43.32% 40.95% 41.36% 42.48% 43.93% 36.59% 36.56%
Total liabilities 46.83% 50.03% 50.32% 51.50% 51.34% 49.17% 48.25% 50.44% 50.19% 50.94% 51.18% 52.27% 53.83% 55.16% 55.88% 51.86% 52.84% 53.08% 54.89% 49.68% 51.29%
Preferred stock, $100 par value; none issued 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Common stock, $1 par value 0.66 0.63 0.68 0.71 0.74 0.74 0.77 0.75 0.78 0.77 0.78 0.78 0.76 0.76 0.76 0.90 0.90 0.90 0.86 0.98 0.96
Capital in excess of par value 23.79 22.56 24.14 24.90 25.88 25.80 26.38 25.68 26.57 26.00 26.37 26.01 25.31 25.02 25.21 26.50 26.51 26.44 25.20 28.44 27.75
Retained earnings 46.03 40.72 40.13 38.74 38.83 37.84 37.31 35.33 34.96 33.25 32.44 31.09 29.24 28.08 27.59 32.19 31.20 30.34 27.82 30.63 29.07
Treasury stock at cost -13.43 -9.87 -10.64 -10.99 -11.53 -8.97 -7.91 -7.66 -7.99 -6.52 -6.20 -5.65 -5.52 -5.48 -5.54 -6.60 -6.10 -5.02 -4.28 -4.80 -4.72
Accumulated other comprehensive items -3.89 -4.07 -4.64 -4.85 -5.26 -4.59 -4.80 -4.54 -4.51 -4.44 -4.57 -4.50 -3.61 -3.53 -3.90 -4.85 -5.35 -5.74 -4.49 -4.93 -4.35
Shareholders’ equity 53.17% 49.97% 49.68% 48.50% 48.66% 50.83% 51.75% 49.56% 49.81% 49.06% 48.82% 47.73% 46.17% 44.84% 44.12% 48.14% 47.16% 46.92% 45.11% 50.32% 48.71%
Total liabilities and shareholders’ equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-Q (filing date: 2021-05-07), 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-01), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-02), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-28), 10-Q (filing date: 2017-11-03), 10-Q (filing date: 2017-08-04), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Thermo Fisher Scientific Inc.’s current liabilities as a percentage of total liabilities and shareholders’ equity increased from Q3 2020 to Q4 2020 but then slightly decreased from Q4 2020 to Q1 2021 not reaching Q3 2020 level.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Thermo Fisher Scientific Inc.’s long-term liabilities as a percentage of total liabilities and shareholders’ equity decreased from Q3 2020 to Q4 2020 but then slightly increased from Q4 2020 to Q1 2021.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Thermo Fisher Scientific Inc.’s total liabilities as a percentage of total liabilities and shareholders’ equity decreased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.
Shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Thermo Fisher Scientific Inc.’s shareholders’ equity as a percentage of total liabilities and shareholders’ equity increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.